Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2006-10-24
2006-10-24
Habte, Kahsay (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C546S070000
Reexamination Certificate
active
07125885
ABSTRACT:
The present invention provides compounds having the formula:wherein R1, R2, R, R′ and the subscript p are described herein. The compounds are useful in the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor. Pharmaceutical compositions and methods of using these compounds for the treatment and/or prevention of a condition or disorder mediated by a G-protein coupled receptor, such as eating disorder, obesity, anxiety disorders and mood disorders are also provided.
REFERENCES:
patent: 4115538 (1978-09-01), Satoh et al.
patent: 5049655 (1991-09-01), Vaughan et al.
patent: 5272146 (1993-12-01), Haugwitz et al.
patent: 5436128 (1995-07-01), Harpold et al.
patent: 5441956 (1995-08-01), Vecchietti et al.
patent: 5449766 (1995-09-01), Vaughan et al.
patent: 5457208 (1995-10-01), Portoghese et al.
patent: 5530095 (1996-06-01), Vaughn et al.
patent: 5849708 (1998-12-01), Maratos-Flier
patent: 6033872 (2000-03-01), Bergsma et al.
patent: 6809104 (2004-10-01), Chen et al.
patent: 2003/0023085 (2003-01-01), Chen et al.
patent: 2003/0176694 (2003-09-01), Chen et al.
patent: 2003/0199549 (2003-10-01), Burnett et al.
patent: 2004/0147538 (2004-07-01), Chen et al.
patent: 0 257 701 (1987-08-01), None
patent: 02 73 4135 (2005-04-01), None
patent: 02 734 1353 (2005-12-01), None
patent: 4-368384 (1992-12-01), None
patent: 2001226269 (2001-08-01), None
patent: WO91/07966 (1991-06-01), None
patent: WO94/07896 (1994-04-01), None
patent: WO95/13071 (1995-05-01), None
patent: WO96/23793 (1996-08-01), None
patent: WO98/31684 (1998-07-01), None
patent: WO99/28492 (1998-12-01), None
patent: WO99/64002 (1999-06-01), None
patent: WO00/15793 (1999-09-01), None
patent: WO00/22129 (1999-10-01), None
patent: WO00/39279 (1999-12-01), None
patent: WO00/40725 (1999-12-01), None
patent: WO00/49170 (2000-01-01), None
patent: WO00/21577 (2000-04-01), None
patent: WO00/75166 (2000-06-01), None
patent: WO01/05947 (2000-07-01), None
patent: WO01/07606 (2000-07-01), None
patent: WO01/07611 (2000-07-01), None
patent: WO00/49046 (2000-08-01), None
patent: WO01/21577 (2000-09-01), None
patent: WO00/70347 (2000-11-01), None
patent: WO01/36479 (2000-11-01), None
patent: WO01/21169 (2001-03-01), None
patent: WO01/68706 (2001-03-01), None
patent: WO01/70975 (2001-03-01), None
patent: WO01/87834 (2001-11-01), None
patent: WO02/002744 (2002-01-01), None
patent: WO02/03070 (2002-01-01), None
patent: WO02/04433 (2002-01-01), None
patent: WO02/06245 (2002-01-01), None
patent: WO02/032897 (2002-04-01), None
patent: WO02/051809 (2002-07-01), None
patent: WO02/057233 (2002-07-01), None
patent: WO02/076929 (2002-10-01), None
patent: WO02/076947 (2002-10-01), None
patent: WO02/083134 (2002-10-01), None
patent: WO02/094799 (2002-11-01), None
patent: WO02089729 (2002-11-01), None
patent: WO03/060475 (2003-07-01), None
patent: PCT/US03/35543 (2004-04-01), None
Yuguang Shi {Peptides 25 (2004) 1605-1611}.
Aceto, MD et al., “Dependence studies of new compounds in the Rhesus monkey, rat and mouse”, (1997) Department of Pharmacology and Toxicology, Medical College of Virginia Commonwealth University, pp. 363-407.
Bergman et al., 1980 ACTA Chemica Scandinavica, Series B; Organic Chemistry and Biochemistry B34(10):763-66.
Berridge, et al. “Inositol Triphosphate, a Novel Second Messenger In Cellular Signal Transduction”, Nature (1984) 312:315-321.
Blechert, S. et al., “Domino reactions—New concepts in the synthesis of indole alkaloids and other polycyclic indole derivatives”, (1995) Insitut Für Organische Chemie, Sekr. C3, Technische Universität Berlin, Straβe des 17 Juni 135, D-10623 Berlin, Germany pp. 592-604.
Boutin et al., (2002) “Melanin-Concentrating Hormone and its Receptors: State of the Art,” Can, J. of Physio. and Pharmacol. 80: 388-395.
Chambers, et al. “Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1”, Nature (1999) 400: 261-265.
Chambers et al., “Melanin-concentrating hormone is the cognate ligand for the orphan G-protein-coupled receptor SLC-1”Nature, (1999) 400:261-65.
Felley-Bosco, et al. “Constitutive Expression of Inducible Nitric Oxide Synthase in Human Brochial Epithelial Cells Induces c-fos and Stimulates the cGMP Pathway”, Am J. Respir Cell. Mol. Biol. (1994) 11: 159-164.
Fujii, H. et a., “A novel abnormal rearrangement in the fishcer indole synthesis”, (1997)Heterocycles45:2109-2112.
Gonzalez, et al. “alpha-Melanocyte-stimulating hormone (alpha-MSH) and melanin-concentrating hormone (MCH) modify monoaminergic levels in the preoptic area of the rat”Peptides(1997) 18:387-392.
Gonzalez, et al., “Behavioral Effects of α-MSH and MCH After Central Administration in the Female Rat”Peptides(1996) 17(1):171-177.
Gouyette, A. et al., “Synthesis, DNA intercalation and antitumor activity of 9-hdroxy-11-demethylellipticine and some derivatives. Comparison with the corresponding ellipticines”, (1980)Euro. J. Med. Chem.15:503-510.
Guillonneau, C. et al., “Synthesis of 9-O-substituted derivatives of 9-hydroxy-5,6-dimethyl-6H-pyrido[4,3-b]carbazole-l-carboxylic acid (2-(dimethylamino)ethyl)amide and their 10-and 11-methyl analogues with improved anititumor activity”, (1990)J. Med. Chem.42:2191-2203.
Ishikura et al., “A Novel Entry to Pyrido [4,3-b] Carbazole: An Efficient Synthesis of Ellipticine”, Chemical Abstract, vol. 132, Abstract 237230, 2000.
Jones, RM et al., “5'-Guanidinonaltrindole, a highly selective and potent k-opioid receptor atagonist”(2000)Euro. J. Med. Chem.396:49-52.
Langlois et al., (975) Tetrahedron Letters 11: 955-958.
Lipkowski, A W et al., “Benzomorphan alkaloids: natural peptidomimetics of opioid peptide pharmacophores”, (1995)Letters in Peptide Science, 2:177-181.
Monzon, et al., “Response to Novelty After I.C.V. Injection of Melanin-Concentrating Hormone (MCH) in Rats”Physiol. Behav.(1999) 67(5):813-817.
Offerman, et al. “Gα15and Gα16Couple A Wide Variety of Receptors to Phospholipase C”, The J. of Biological chemistry (1995), 270(25) pp. 15175-15180.
Olmsted, SL et al., “A remarkable change of opioid receptor selectivity on the attachment of a peptidomimetric κ address element to the δ antagonist, naltrindole: 5'-[(N2-alkylamidino)methyl]naltrindole derivatives as a novel class of κ opioid receptor antagonists” (1993)J. Med. Chem.36:179-180.
Portoghese, PS et al., “Naltrindole 5'-isothiocyanate: a nonequilibrium, higly selective δ opioid receptor antagonist” (1990)J. Med. Chem.33:1547-1548.
Portoghese, PS et al., “Design of peptidomimetic δ opioid receptor antagonists using the message-address concept” (1990)J. Med. Chem.33:1714-1720.
Portoghese, PS et al., “Application of the message-address concept in the design of highly potent and selective non-peptide δ opioid receptor antagonists”, (1988)J. Med. Chem.31:281-282.
Portoghese, PS et al., “7'-substituted amino acid conjugates of naltrindole. Hydrophillic groups as determinants of selective antagonism of δ, opioid receptor-mediated antinociception in mice.” (1995)J. Med. Chem.38:402-407.
Rai, et al., “Synthesis, P {hysicochemical Properties, and Evaluation of N-Substituted-2-Alkyl-3-Hydroxy-4(1H)-Pyridones” J.. Med. Chem. (1998) 41:3347-3359.
Rastogi, et al. 1987 “Synthesis, Neuroleptic & Antiinflammatory Activites of 4a, 11a-cis-&trans-2-[γ-(p-Fluorobenzoyl)proppyl]-1,2,3,4,4a,5,11,11 a-octahydro-6H-pyriod[4,3-b]carbazoles & Related Derivatives,”India Journal of Chemistry26B: 335-340.
Saito, et al. “Molecular characterization of the melanin-concentrating-hormone receptor”,Nature(1999) 400: 265-269.
Saito, et al., “Melanin-concentrating hormone receptor: an orphan receptor fits the key”Trends Endocri
Chen Xiaoqi
Fan Pingchen
Jaen Juan
Li Leping
Lizarzaburu Mike
Amgen Inc.
Habte Kahsay
LandOfFree
Fused heterocyclic compounds does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused heterocyclic compounds, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heterocyclic compounds will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3640660